WASHINGTON (dpa-AFX) - CytomX Therapeutics, Inc. said Friday that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
The number of shares to be offered and the price range for the offering have not yet been determined.
CytomX plans to list its common stock under the symbol 'CTMX' on the NASDAQ Global Market.
BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will act as joint book-running managers for the offering. Oppenheimer & Co. will serve as manager for the offering.
South San Francisco, California-based CytomX Therapeutics is a biopharmaceutical company developing Probody therapeutics for the treatment of cancer.
Copyright RTT News/dpa-AFX